For the first time in 50 years, two new drugs are available to patients battling the most trenchant forms of tuberculosis.
News & stories
Two patient stories from IRD's project in Pakistan.
Médecins Sans Frontières (MSF), Partners In Health (PIH) and other leading medical organizations have launched a major clinical trial which seeks to revolutionize treatment for the toughest strains of tuberculosis (TB).
Wondering what endTB’s clinical trial aims to achieve, exactly? Watch this MSF-produced video to find out more.
Multidrug-resistant tuberculosis is a mounting health crisis, but a new MSF initiative could lead to better treatments for patients around the world.
Attending the Union conference in Liverpool this week (26-29 October) ? Don’t miss these events from endTB and partners.
Three of the first patients who received Bedaquiline through endTB, led by Partners in Health in Kazakhstan, tell their stories of having MDR-TB.
Partners In Health in Peru started the first set of XDR-TB patients on a new drug regimen now available through endTB, and results so far border on the miraculous.
An XDR-TB patient describes her joy after an arduous recovery -- and the long, toxic treatment it took to get there.
Partners In Health’s Dr. KJ Seung, an endTB project leader, discusses rolling out treatment in Lesotho.
MSF appreciates Otsuka’s donation of 400 treatments of a novel drug, delamanid, which enables MSF and its partners to initially treat a specific number of MDR-TB patients worldwide.
Why is MDR-TB such a pressing concern? This MSF video explains.
Partners In Health (PIH), Médecins Sans Frontières (MSF), Interactive Research and Development (IRD) and their financial partner UNITAID will start in April the endTB project, a partnership aimed at radically changing the management of multidrug-resistant tuberculosis (MDR-TB).